Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.
Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.
Encompass Health Corp EVP & CFO Douglas Coltharp reported a combination of option exercise and share sales in Encompass Health Common Stock. He exercised 27,694 shares from a non-qualified stock option at an exercise price of $32.94 per share and acquired the same number of common shares.
On the same date, he sold a total of 27,694 shares of common stock in open-market transactions at weighted average prices of about $106.83 and $107.28 per share, leaving 69,377 directly held shares. The option grant, originally exercisable until October 28, 2026, now has 0 options remaining after this exercise.
Indirect holdings reported after these transactions include 37,749 shares held by his spouse, 125,631 shares held by an irrevocable trust for the benefit of children, and 27,480 shares held by another irrevocable trust. A footnote states the option terms were adjusted under the 2016 Omnibus Performance Incentive Plan for the spin-off distribution of Enhabit, Inc.
Encompass Health Corporation has agreed to issue $500 million in aggregate principal amount of 5.875% senior notes due 2034 in a private offering, with closing expected on or about May 29, 2026, subject to the purchase agreement terms. The notes will be guaranteed on a senior unsecured basis by certain subsidiaries and sold to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S.
The company currently intends to use the net proceeds, together with cash on hand, to redeem at par $400 million of its outstanding 4.500% Senior Notes due 2028, repay $100 million under its senior secured revolving credit facility, and pay related fees and expenses. Encompass Health describes itself as the largest owner and operator of inpatient rehabilitation hospitals in the United States, with 175 hospitals in 39 states and Puerto Rico.
Encompass Health Corp executive Patrick William Tuer, EVP and Chief Operating Officer, reported an open-market sale of Encompass Health Common Stock. He sold 682 shares at a price of $104.56 per share on May 11, 2026, and held 24,755 shares directly after this transaction.
Encompass Health Corporation reported the results of its Annual Meeting held on May 7, 2026. Stockholders voted on electing ten directors, ratifying PricewaterhouseCoopers LLP as independent auditor, and approving the compensation of named executive officers.
There were 99,565,304 common shares outstanding as of the record date, with each share entitled to one vote. Votes representing 92.5% of the combined voting power were present by proxy. All ten director nominees received strong support, with votes for each nominee ranging from about 83.9 million to 85.9 million.
Ratification of PricewaterhouseCoopers LLP passed with 88,444,873 votes for, 3,608,490 against, and 68,452 abstentions. The advisory vote on executive compensation (say-on-pay) passed with 83,410,829 votes for, 3,006,776 against, and 102,636 abstentions, along with 5,601,574 broker non-votes on both the director and compensation proposals.
O'Connor Kevin J. reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Kevin J. O'Connor received a grant of 1,634 shares of Encompass Health Common Stock. The shares were awarded at no cash cost as part of his annual restricted stock unit grant under the Corporation's 2025 Omnibus Performance Incentive Plan. Following this equity award, O'Connor directly holds 11,563 shares of Encompass Health Common Stock, reflecting a routine compensation-related increase in his ownership stake.
Christie Edward M III reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp reported that director Edward M. Christie III received an annual equity award in the form of 1,634 shares of Encompass Health Common Stock on May 7, 2026. The shares were granted at $0.00 per share as restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan, meaning they are compensation rather than a market purchase.
After this award, Christie directly owns 9,086 shares of Encompass Health Common Stock. This is a routine director compensation grant, not an open‑market buy or sale, and it does not reflect a discretionary trading decision.
Reidy Christopher R reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Christopher R. Reidy received an equity grant of 1,634 shares of Encompass Health Common Stock. The shares were awarded at a price of $0.00 per share as part of his annual grant of restricted stock units under the corporation's 2025 Omnibus Performance Incentive Plan.
Following this grant, Reidy directly holds 17,437 shares of Encompass Health Common Stock. This transaction reflects a compensation-related award rather than an open-market purchase or sale.
Hayes Cain A reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Cain A. Hayes reported receiving an annual grant of 1,634 shares of Encompass Health Common Stock, awarded as restricted stock units under the corporation's 2025 Omnibus Performance Incentive Plan. After this compensation-related award, Hayes directly holds 2,092 shares.